Benitec Biopharma Inc
BNTC
NASDAQ
Biotechnology
$12.56
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $431.49M
Volume 169.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-48.88M
TTM
-100.4%
YoY
Operating Cash Flow
$-19.79M
TTM
-63.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 8.8 | 13.5 | 6.4 | 7.5 | 7.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 15.3 | 17.2 | 9.8 | 13.4 | 13.6 |
Operating Income | -15.3 | -17.2 | -9.8 | -13.4 | -13.6 |
EBITDA | -15.3 | -17.2 | -9.8 | -13.4 | -13.6 |
Other Income / Expense | 0.0 | -0.0 | -0.2 | 0.2 | 0.1 |
Total Other Income / Expense | 0.8 | 1.0 | 0.8 | 1.5 | 1.6 |
Income Before Income Taxes | -14.5 | -16.1 | -9.0 | -11.8 | -11.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -14.5 | -16.1 | -9.0 | -11.8 | -11.9 |
Consolidated Net Income / Loss | -14.5 | -16.1 | -9.0 | -11.8 | -11.9 |
Net Income Attributable to Common Shareholders | -14.5 | -16.1 | -9.0 | -11.8 | -11.9 |
Basic EPS | -$0.38 | -$0.39 | -$0.22 | -$0.26 | -$0.24 |
Diluted EPS | -$0.38 | -$0.39 | -$0.22 | -$0.26 | -$0.24 |
Basic Shares Outstanding | 38.6M | 41.1M | 41.5M | 46.0M | 49.4M |
Diluted Shares Outstanding | 38.6M | 41.1M | 41.5M | 46.0M | 49.4M |